Next report date
Report period
Q1 2024
EPS estimate
−0.20EUR
Revenue estimate
5.89 MEUR
−1.3217EUR
−233.60 MEUR
159.67 MEUR
183.15 M
About SANGAMO THERAP.INC.DL-,01
Sector
Industry
CEO
Alexander D. Macrae
Website
Headquarters
Richmond
Employees (FY)
405
Founded
1995
FIGI
BBG001KNMS80
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SANGAMO THERAP.INC.DL-,01 stocks are traded under the ticker GBY.
SANGAMO THERAP.INC.DL-,01 is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
GBY earnings for the last quarter are −0.56 EUR per share, whereas the estimation was −0.30 EUR resulting in a −85.03% surprise. The estimated earnings for the next quarter are −0.23 EUR per share. See more details about SANGAMO THERAP.INC.DL-,01 earnings.
SANGAMO THERAP.INC.DL-,01 revenue for the last quarter amounts to 8.89 M EUR despite the estimated figure of 8.85 M EUR. In the next quarter revenue is expected to reach 7.34 M EUR.
Yes, you can track SANGAMO THERAP.INC.DL-,01 financials in yearly and quarterly reports right on TradingView.
GBY net income for the last quarter is −54.63 M EUR, while the quarter before that showed −98.54 M EUR of net income which accounts for 44.56% change. Track more SANGAMO THERAP.INC.DL-,01 financial stats to get the full picture.
No, GBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAP.INC.DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 405.00 employees. See our rating of the largest employees — is SANGAMO THERAP.INC.DL-,01 on this list?
We've gathered analysts' opinions on SANGAMO THERAP.INC.DL-,01 future price: according to them, GBY price has a max estimate of 7.36 EUR and a min estimate of 0.92 EUR. Read a more detailed SANGAMO THERAP.INC.DL-,01 forecast: see what analysts think of SANGAMO THERAP.INC.DL-,01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAP.INC.DL-,01 EBITDA is −85.21 M EUR, and current EBITDA margin is −52.26%. See more stats in SANGAMO THERAP.INC.DL-,01 financial statements.